Success Metrics

Active Trials

7(88%)

Phase Distribution

Ph phase_3

63%

Ph phase_1

13%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

1(12.5%)

Phase 2Efficacy & side effects

2(25.0%)

Phase 3Large-scale testing

5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Detailed Status

Recruiting6

Active, not recruiting1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 11 (12.5%)

Phase 22 (25.0%)

Phase 35 (62.5%)

Trials by Status

active_not_recruiting113%

not_yet_recruiting113%

recruiting675%

Recent Activity

7 active trials

Showing 5 of 8

recruitingphase_3

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

NCT07564141

recruitingphase_3

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

NCT07225270

not_yet_recruitingphase_3

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

NCT07604766

recruitingphase_2

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

NCT07539311

recruitingphase_2

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

NCT07288177

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT07564141Phase 3

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

Recruiting

NCT07225270Phase 3

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Recruiting

NCT07604766Phase 3

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

Not Yet Recruiting

NCT07539311Phase 2

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

Recruiting

NCT07288177Phase 2

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Recruiting

NCT07166094Phase 3

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

Recruiting

NCT05579366Phase 1

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Recruiting

NCT06619236Phase 3

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

Active Not Recruiting

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8